The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tilg, H.
Right arrow Articles by Dinarello, C. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tilg, H.
Right arrow Articles by Dinarello, C. A.

The Journal of Immunology, Vol 150, Issue 10 4687-4692, Copyright © 1993 by American Association of Immunologists

ARTICLES

Induction of circulating IL-1 receptor antagonist by IFN treatment

H Tilg, JW Mier, W Vogel, WE Aulitzky, CJ Wiedermann, E Vannier, C Huber and CA Dinarello
Department of Medicine, New England Medical Center Hospitals, Boston, MA 02111.

This study was undertaken to determine whether IFN induce IL-1 receptor antagonist (IL-1Ra), a specific inhibitor of IL-1. Plasma samples were obtained from healthy volunteers (n = 5) and patients with chronic hepatitis C (n = 5) treated with IFN-alpha, and from patients with renal cell carcinoma (n = 6) treated with IFN-gamma and assayed for IL- 1Ra by a specific radioimmunoassay. Both types of IFN were administered subcutaneously. In vitro studies were carried out with PBMC from healthy volunteers. A single, low and nontoxic dose (1 x 10(6) U) of IFN-alpha induced circulating IL-1Ra, which reached peak levels within 12 h. This effect was dose-dependent and more pronounced with a higher dose (5 x 10(6) U). Peak IL-1Ra levels 12 h after 5 x 10(6) U IFN-alpha were 4.16 +/- 0.35 ng/ml in healthy volunteers and 5.7 +/- 0.73 ng/ml in patients with chronic hepatitis C (difference not significant). Thereafter levels declined but remained elevated for 24 h. IFN-gamma treatment led only to a modest increase of circulating IL-1Ra even at a dose of 400 micrograms; this dose, however, was associated with side effects similar to those seen after injection of 5 x 10(6) U IFN-alpha. PBMC stimulated with IFN-alpha or IFN-gamma produced IL-1Ra in vitro. The induction of IL-1Ra may contribute to the antiviral, anti- inflammatory, and antiproliferative effects of IFN.


This article has been cited by other articles:


Home page
 EndocrinologyHome page
Z. T. Resch, B.-K. Chen, L. K. Bale, C. Oxvig, M. T. Overgaard, and C. A. Conover
Pregnancy-Associated Plasma Protein A Gene Expression as a Target of Inflammatory Cytokines
Endocrinology, March 1, 2004; 145(3): 1124 - 1129.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
H Tilg, H Vogelsang, O Ludwiczek, H Lochs, A Kaser, J-F Colombel, H Ulmer, P Rutgeerts, S Kruger, A Cortot, et al.
A randomised placebo controlled trial of pegylated interferon {alpha} in active ulcerative colitis
Gut, December 1, 2003; 52(12): 1728 - 1733.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
C. Maihofner, M. P. Charalambous, U. Bhambra, T. Lightfoot, G. Geisslinger, N. J. Gooderham, and The Colorectal Cancer Group
Expression of cyclooxygenase-2 parallels expression of interleukin-1beta, interleukin-6 and NF-kappaB in human colorectal cancer
Carcinogenesis, April 1, 2003; 24(4): 665 - 671.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
K. G. Veenstra, Z. L. Jonak, S. Trulli, and J. A. Gollob
IL-12 Induces Monocyte IL-18 Binding Protein Expression Via IFN-{gamma}
J. Immunol., March 1, 2002; 168(5): 2282 - 2287.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. M. Reuben, B.-N. Lee, H. Johnson, H. Fritsche, H. M. Kantarjian, and M. Talpaz
Restoration of Th1 Cytokine Synthesis by T Cells of Patients with Chronic Myelogenous Leukemia in Cytogenetic and Hematologic Remission with Interferon-{{alpha}}
Clin. Cancer Res., May 1, 2000; 6(5): 1671 - 1677.
[Abstract] [Full Text]

Home page
 Proc. Natl. Acad. Sci. USAHome page
V. Agnello, G. Abel, M. Elfahal, G. B. Knight, and Q.-X. Zhang
Hepatitis C virus and other Flaviviridae viruses enter cells via low density lipoprotein receptor
PNAS, October 26, 1999; 96(22): 12766 - 12771.
[Abstract] [Full Text] [PDF]

Home page
 Arch OphthalmolHome page
A. A. Okada
Cytokine Therapy in Eye Disease
Arch Ophthalmol, November 1, 1998; 116(11): 1514 - 1516.
[Full Text] [PDF]

Home page
 J Natl Cancer Inst MonogrHome page
S. E. Krown
Clinical Overview: Issues in Kaposi's Sarcoma Therapeutics
J Natl Cancer Inst Monographs, April 1, 1998; 1998(23): 59 - 63.
[Abstract] [Full Text]

Home page
 BloodHome page
N. Noraz, J. L. Lathey, and S. A. Spector
Human Cytomegalovirus-Associated Immunosuppression Is Mediated Through Interferon-alpha
Blood, April 1, 1997; 89(7): 2443 - 2452.
[Abstract] [Full Text] [PDF]

Home page
 Innate ImmunityHome page
C.A. Dinarello
Blocking interleukin-1 in sepsis
Innate Immunity, June 1, 1995; 2(3): 157 - 162.
[Abstract] [PDF]

Home page
 Innate ImmunityHome page
J. Sivo, C.A. Salkowski, A.D. Politis, and S.N. Vogel
Differential regulation of LPS-induced IL-1 and EL-1 receptor antagonist mRNA by IFN{alpha} and IFN{gamma} in murine peritoneal macrophages
Innate Immunity, March 1, 1994; 1(1): 30 - 37.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1993 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1993 by The American Association of Immunologists, Inc. All rights reserved.